ExamPat

Padmashri Ponnaluri

USPTO Patent Examiner·Active 2012 to 2024

Padmashri Ponnaluri is a USPTO patent examiner who has handled 54 ex parte reexaminations between 2012 and 2024. These reexams concentrate in Chemistry & Materials, Life Sciences & Consumer, and Physics & Instruments. ExamPat indexes the full prosecution record for each of these cases, including office-action grounds, certificate outcomes, and downstream PTAB and federal-circuit decisions.

Filings by year

8
12
6
13
6
14
4
15
4
16
4
17
5
18
5
19
1
20
4
21
3
22
5
23
2
24

Technology mix

Chemistry & Materials37 (65%)
Life Sciences & Consumer18 (32%)
Physics & Instruments2 (4%)

Compare against all examiners

Eight side-by-side metrics: case volume, pendency, OAs per reexam, rejection mix, SNQ denial rate, certification rate, and PTAB appeal rate, with a Δ column showing where this examiner runs higher or lower than the corpus.

  • Average and median pendency, both for this examiner and the corpus
  • Rejection basis split (102 / 103 / 112) head-to-head
  • Certification, SNQ denial, and PTAB appeal rates

Certificate outcome distribution

How this examiner's certificates split across the six possible outcomes: all claims confirmed, confirmed with amendment, confirmed with new claims, mixed, or all claims canceled. Includes share comparison to the corpus distribution.

  • Count and share for each of the six outcome buckets
  • Δ vs. corpus distribution in percentage points
  • Useful for setting realistic patent-owner expectations

Event-to-event timing

Median time for this examiner's cases at each prosecution stage — filing to first office action, filing to NIRC, and filing to certificate — with corpus comparison and sample size.

  • Median in months per transition
  • Side-by-side with the corpus median
  • n column showing how many of this examiner's cases completed each transition

Recent reexaminations (showing 25 of 54)

Control #FiledPatentTitlePendencyStatus
90/019,445Apr 11, 20249,951,378NOVEL COMPOSITIONS, METHODS AND KITS FOR REAL TIME POLYMERASE CHAIN REACTION (PCR)15 moClosed
90/019,379Jan 17, 202411,608,491SUSPENSION SYSTEM FOR ADENO ASSOCIATED VIRUS PRODUCTION13 moClosed
90/019,313Nov 30, 202311,583,556MODIFIED CELLS AND METHODS OF THERAPY22 moClosed
90/019,297Nov 8, 202311,680,252PET HYDROLASE HAVING IMPROVED THERMAL STABILITY8 moClosed
90/019,225Jul 6, 202310,327,400METHODS FOR IDENTIFYING CROSSES FOR USE IN PLANT BREEDING11 moClosed
90/015,234May 16, 202311,623,941SEPARATION METHOD11 moClosed
90/015,214Mar 22, 202310,995,338METHOD FOR REMOVING GENETIC LINKAGE IN A PLANT12 moClosed
90/015,171Nov 30, 202211,089,765GENETICALLY MODIFIED RAT MODELS FOR SEVERE COMBINED IMMUNODEFICIENCY (SCID)12 moClosed
90/015,047Jun 7, 202211,351,252SELECTIVELY ALTERING MICROBIOTA FOR IMMUNE MODULATION14 moClosed
90/015,048Jun 7, 202211,291,723SELECTIVELY ALTERING MICROBIOTA FOR IMMUNE MODULATION18 moClosed
90/014,910Nov 23, 202110,913,768COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS9 moClosed
90/014,883Oct 15, 202110,829,737Chimeric Receptor with NKG2D Specificity for Use in Cell Therapy Against Cancer and Infectious Disease17 moClosed
90/014,779Jun 21, 20219,511,092A Chimeric Receptor With NKG2D Specificity For Use In Cell Therapy Against Cancer And Infectious Disease19 moClosed
90/014,705Mar 23, 202110,953,090SELECTIVELY ALTERING MICROBIOTA FOR IMMUNE MODULATION42 moClosed
90/014,449Feb 11, 202010,406,226METHOD OF MANUFACTURING VEGF ANTAGONIST FUSION PROTEINS45 moClosed
90/014,423Dec 20, 20197,588,755DNA SEQUENCES, RECOMBINANT DNA MOLECULES AND PROCESSES FOR PRODUCING HUMAN FIBROBLAST INTERFERON-LIKE POLYPEPTIDES51 moClosed
90/014,395Oct 24, 201910,022,435Nucleic Acid Vaccines14 moClosed
90/014,320Jun 19, 20199,574,209ENHANCED NUCLEIC ACID CONSTRUCTS FOR EUKARYOTIC GENE EXPRESSION13 moClosed
90/014,318Jun 19, 20199,428,767ENHANCED NUCLEIC ACID CONSTRUCTS FOR EUKARYOTIC GENE EXPRESSION17 moClosed
90/014,299May 3, 20199,745,381BISPECIFIC SCFV IMMUNOFUSION (BIF)18 moClosed
90/014,218Oct 5, 20187,625,558COMPOSITIONS AND METHODS OF TREATING TUMORS6 moClosed
90/014,167Aug 17, 20189,872,900NUCLEIC ACID VACCINES9 moClosed
90/014,181Aug 8, 20188,293,779MAZINDOL COMBINATION IN THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY13 moClosed
90/014,165Jul 13, 20189,745,381Bispecific ScFV Immunofusion (BIf)28 moClosed
90/014,140May 18, 20188,962,271FRUCTOSYL PEPTIDYL OXIDASE16 moClosed

Other USPTO reexam examiners

Get the full reexam analytics

Compare Padmashri Ponnaluri against the full corpus, see the certificate-outcome split, drill into event timing, filter the case list, and export. Free to sign up.